Clinical Trials
155 trialsMajesTEC-1
Janssen Research & Development, LLC
MonumenTAL-1
Janssen Research & Development, LLC
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Janssen Research & Development, LLC
A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
AbbVie
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Newave Pharmaceutical Inc
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Incyte Corporation
MK-1026-005
Merck Sharp & Dohme LLC
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Immunome, Inc.
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
Hangzhou Sumgen Biotech Co., Ltd.
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
Kumquat Biosciences Inc.
Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies
Tcelltech Inc.
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Vanda Pharmaceuticals
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Kura Oncology, Inc.
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ascentage Pharma Group Inc.
SPI-FOL-102
Acrotech Biopharma Inc.
This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.
Nanjing RegeneCore Biotech Co., Ltd.
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Prelude Therapeutics
Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.
Byondis B.V.
A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies
Qilu Pharmaceutical Co., Ltd.
A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies
Qilu Pharmaceutical Co., Ltd.
A Phase I Study of BR108 in Hematological Malignancies
BioRay Pharmaceutical Co., Ltd.
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Incyte Corporation
Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
Acrotech Biopharma Inc.
A Clinical Study of HMPL-506 in Patients With Hematological Malignancies
Hutchmed
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy
Sichuan Baili Pharmaceutical Co., Ltd.
The Study of ICP-248 in Patients With Mature B-cell Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.
Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies
Constellation Pharmaceuticals
Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment
Novartis
Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia
Hangzhou Weben Pharma Co., Ltd
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Servier
Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects
Kangpu Biopharmaceuticals, Ltd.
A Study of DT2216 in Relapsed/Refractory Malignancies
Dialectic Therapeutics, Inc
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Tr1X, Inc.
First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
Onward Therapeutics
SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.
Hangzhou Sumgen Biotech Co., Ltd.
A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
Pfizer
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
Shenzhen TargetRx Co., Ltd.
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
AbbVie
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Ipsen
A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
Hangzhou DAC Biotechnology Co., Ltd.
Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients
Biohaven Pharmaceuticals, Inc.
Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
Gilead Sciences
Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.
CYNK001AML01
Celularity Incorporated
ANGELICA
CytoMed Therapeutics Pte Ltd
A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
Astellas Pharma Inc
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Vincerx Pharma, Inc.